



UniversityHospital Heidelberg

Teaching Course Stroke TC 2

*Update on extracranial carotid stenosis:
How best to diagnose, how best to treat?*

Peter A. Ringleb

Department of Neurology

Peter.Ringleb@med.uni-heidelberg.de



Disclosures

Peter A. Ringleb, MD



- Professor of Vascular Neurology and head of the Stroke service at the University hospital Heidelberg (GER)
- Member of the WSO, ESO, DGN, DSG, DGNI, DEGUM
- Secretary of the German Stroke Society
- National Coordinator of SITS
- **Clinical Coordinator of SPACE,
Member of the Steering-Committee of SPACE-2**
- Member of the Steering-Committee of ECASS4
- Member of the Ethics Committee of the Medical Faculty of Heidelberg
- Lecture-fees and travel-expenses from Bayer, Boehringer Ingelheim, Covidien, Daiichi Sankyo, Ferrer, Glaxo Smith Kline, Lilly, Paion, Sanofi



Objective

Carotid artery stenosis (CS)

- Learn about validity of non-invasive diagnostic tools
- Discussion about the validity of older trials for treatment of asymptomatic CS
- Comparison of carotid artery stenting (CAS) and carotid endarterectomy (CEA) for treatment of patients with asymptomatic or symptomatic CS
- Learn about patient characteristic, which justify CAS in patients with symptomatic CS



Agenda

Carotid artery stenosis


- Diagnosis
- Case-Discussion
- Trial-Summary
- Subgroup-Discussion
- Summary






Carotid artery stenosis

Quantification



- ECST $(1 - A / B) \times 100\%$
- NASCET $(1 - A / C) \times 100\%$





Carotid artery stenosis

Comparison of non-invasive methods with DSA

	DUS	CTA	MRA	CEMRA
70-99% stenosis				
Sensitivity (95% CI)	0.89 (0.85-0.92)	0.77 (0.68-0.84)	0.88 (0.82-0.92)	0.94 (0.88-0.97)
Specificity (95% CI)	0.84 (0.77-0.89)	0.95 (0.91-0.97)	0.84 (0.76-0.97)	0.93 (0.89-0.96)
50-69% stenosis				
Sensitivity (95% CI)	0.36 (0.25-0.49)	0.67 (0.30-0.90)	0.37 (0.26-0.49)	0.77 (0.59-0.89)
Specificity (95% CI)	0.91 (0.87-0.94)	0.79 (0.63-0.89)	0.91 (0.78-0.97)	0.97 (0.93-0.99)
0-49% stenosis or 100% occluded				
Sensitivity (95% CI)	0.83 (0.73-0.90)	0.81 (0.59-0.93)	0.81 (0.70-0.88)	0.96 (0.90-0.99)
Specificity (95% CI)	0.84 (0.62-0.95)	0.91 (0.74-0.98)	0.88 (0.76-0.95)	0.96 (0.90-0.99)



Carotid artery stenosis

Ultrasound grading

Degree of Stenosis as Defined by NASCET (%)	Grading of Internal Carotid Stenosis							
	10–40	50	60	70	80	90	Occlusion	
Main criteria								
1. B-mode image, diameter	Applicable	Possibly applicable						Imaging of occluded artery
2. Color Doppler image	Plaque delineation	Flow	Flow	Flow	Flow	Flow	Absence of flow	
3. PSV threshold (cm/s)		125		230		NA	NA	
4a. PSV average (cm/s)	≤160	210	240	330	370	Variable	NA	
4b. PSV poststenotic (cm/s)				≥50	<50	<30	NA	
5. Collateral flow (periorbital arteries or circle of Willis)				Possible	Present	Present	Present	
Additional criteria								
6. Prestenotic flow (diastole) (CCA)				Possibly reduced	Reduced	Reduced	Reduced	
7. Poststenotic flow disturbances (severity and length)		Moderate	Pronounced	Pronounced	Pronounced	Variable	NA	
8. End-diastolic flow velocity in the stenosis (cm/s)			<100	>100		Variable	NA	
9. Carotid ratio ICA/CCA	<2	≥2	≥2	>4	>4	Variable	NA	



Mr. A.

67 years


- 05.09.2014:
 - Out patient visit, no history of focal neurological symptoms
- Risk factors:
 - Arterial hypertension, Hyperlipidemia
- Examinations:
 - neurological examination normal
 - MRT normal
 - Neurosonology: severe (~80%) stenosis of the left ICA







Asymptomatic carotid artery stenosis

Matter of confusion



Asymptomatic Carotid Artery Stenosis



Primary prevention





Asymptomatic Carotid Artery Stenosis

Primary prevention methods





SPACE-2

Stent-Protected Angioplasty in Asymptomatic Carotid Artery Stenosis vs. Endarterectomy

- Are **CAS** or **CEA** superior to a modern medical therapy (**OMT**) in the primary prevention of ischemic stroke in patients with a severe asymptomatic carotid stenosis?
- Is **CAS** at least non-inferior to **CEA** in terms of safety and efficacy?





SPACE-2


Key in- and exclusion criteria

- 👍 Atherosclerotic carotid stenosis $\geq 70\%$ (ECST)
 - 👍 Age from 50 to 85 yrs.
 - 👍 No stroke or stroke-like symptoms within 180 days
 - 👍 Stenosis treatable with CEA and CAS
-
- 👎 Preexisting disability (modified RS ≥ 2)
 - 👎 Radiation induced stenosis, recurrent stenosis
 - 👎 High grade tandem stenosis
 - 👎 Cardiac embolism source (atrial fibrillation, prosthetic heart valve)
 - 👎 Life expectancy < 5 yrs.



SPACE-2

Protocol Modification






SPACE-2

Study Status as of July 2014

22.10.2014: Decision of the GRF not to fund for new patients
SC decided to stop inclusion of further patients





SPACE-2

Study Status as of August 2015

- 513 patients randomized
- Close out monitoring not finished
- Database clearing in process
- Endpoint events adjudication finalized in about 99%
- Therefore, preliminary results will be demonstrated



Symptomatic carotid artery stenosis

Background

- Extracranial carotid artery stenoses causes approximately 10% of all ischemic strokes¹
- Symptomatic carotid artery stenosis have a high recurrence risk²
- Carotid endarterectomy (CEA) is highly effective in symptomatic (TIA/non disabling stroke) severe carotid artery stenosis³



1: Grau et al., Stroke. 2001;32 (11):2559-2566

2: Rothwell et al., 1996;27 (2):260-265

3: Rothwell PM et al., Lancet (2004); 363: 915-24



Mrs. B.

63 years

- 28.10.2015:
 - Mild weakness of the right arm and speech disturbance
- Risk factors:
 - CHD, Hypertension, Smoking stopped 4 years ago
- Examinations:
 - Neurological exam: normal
 - MRT: small left-hemispheric cortical stroke
 - Ultrasound: Severe (around 80%) stenosis at the origin of the left ICA due to an echolucent plaque






Symptomatic Carotid artery stenosis

Secondary prevention with CEA


- Efficacy of surgery increases with stenosis severity
- Above 50%^{NASCET} surgery is superior to medical treatment





Carotid Artery Stenosis

Treatment options



Randomized clinical trials

CAS vs. CEA

Articles

30 day results from the SPACE trial of stent protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial

The SPACE Collaborative Group

Summary
Background: Carotid endarterectomy (CEA) is effective in reducing stroke in patients with severe symptomatic carotid stenosis and carotid artery revascularisation has been widely used as standard treatment. Carotid artery stenting (CAS) has been investigated as an alternative to CEA. However, the results of randomised trials comparing CEA with CAS are inconclusive.

Methods: 1293 patients with symptomatic carotid stenosis were randomly assigned to CEA (n=647) or CAS (n=646) in the SPACE trial. The primary endpoint was the risk of stroke, death, or myocardial infarction (MACE) within 30 days after randomisation. Secondary endpoints included stroke, death, or MACE within 90 days, and the need for repeat revascularisation. The trial was designed as a non-inferiority trial with a margin of 1.5%.

Results: 1293 patients were included in the analysis. The rate of ipsilateral stroke was 1.4% in the CEA group and 1.5% in the CAS group (P=0.85). The rate of stroke, death, or MACE within 30 days was 10.1% in the CEA group and 10.3% in the CAS group (P=0.85). The rate of stroke, death, or MACE within 90 days was 11.1% in the CEA group and 11.3% in the CAS group (P=0.85). The need for repeat revascularisation was 1.4% in the CEA group and 1.5% in the CAS group (P=0.85).

Conclusion: CAS is non-inferior to CEA for the primary endpoint of stroke, death, or MACE within 30 days. The results of this trial do not support the use of CAS as an alternative to CEA.

Introduction
Carotid endarterectomy (CEA) is the standard treatment for symptomatic carotid stenosis. However, the results of randomised trials comparing CEA with carotid artery stenting (CAS) are inconclusive. The SPACE trial is a randomised non-inferiority trial comparing CEA with CAS in patients with symptomatic carotid stenosis. The primary endpoint was the risk of stroke, death, or myocardial infarction (MACE) within 30 days after randomisation. Secondary endpoints included stroke, death, or MACE within 90 days, and the need for repeat revascularisation. The trial was designed as a non-inferiority trial with a margin of 1.5%.

Method
The SPACE trial was a randomised non-inferiority trial comparing CEA with CAS in patients with symptomatic carotid stenosis. The primary endpoint was the risk of stroke, death, or MACE within 30 days after randomisation. Secondary endpoints included stroke, death, or MACE within 90 days, and the need for repeat revascularisation. The trial was designed as a non-inferiority trial with a margin of 1.5%.

Results
1293 patients were included in the analysis. The rate of ipsilateral stroke was 1.4% in the CEA group and 1.5% in the CAS group (P=0.85). The rate of stroke, death, or MACE within 30 days was 10.1% in the CEA group and 10.3% in the CAS group (P=0.85). The rate of stroke, death, or MACE within 90 days was 11.1% in the CEA group and 11.3% in the CAS group (P=0.85). The need for repeat revascularisation was 1.4% in the CEA group and 1.5% in the CAS group (P=0.85).

Conclusion
CAS is non-inferior to CEA for the primary endpoint of stroke, death, or MACE within 30 days. The results of this trial do not support the use of CAS as an alternative to CEA.

Articles

Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial

*International Carotid Stenting Study Investigators**

Summary
Background: There are an alternative treatment to carotid endarterectomy for symptomatic carotid stenosis, but there is no established equivalence in safety and efficacy. We compared the safety of carotid artery stenting with endarterectomy.

Methods: The International Carotid Stenting Study (ICSS) is a multicentre, international, randomised controlled trial. Patients with symptomatic carotid stenosis were randomly assigned to carotid endarterectomy (CEA) or carotid artery stenting (CAS). The primary endpoint was the risk of stroke, death, or myocardial infarction (MACE) within 30 days after randomisation. Secondary endpoints included stroke, death, or MACE within 90 days, and the need for repeat revascularisation. The trial was designed as a non-inferiority trial with a margin of 1.5%.

Results: 1293 patients were included in the analysis. The rate of ipsilateral stroke was 1.4% in the CEA group and 1.5% in the CAS group (P=0.85). The rate of stroke, death, or MACE within 30 days was 10.1% in the CEA group and 10.3% in the CAS group (P=0.85). The rate of stroke, death, or MACE within 90 days was 11.1% in the CEA group and 11.3% in the CAS group (P=0.85). The need for repeat revascularisation was 1.4% in the CEA group and 1.5% in the CAS group (P=0.85).

Conclusion: CAS is non-inferior to CEA for the primary endpoint of stroke, death, or MACE within 30 days. The results of this trial do not support the use of CAS as an alternative to CEA.

Articles

Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis

*Carotid Artery Stenting Study Investigators**

Summary
Background: Carotid endarterectomy (CEA) is the standard treatment for symptomatic carotid stenosis. However, the results of randomised trials comparing CEA with carotid artery stenting (CAS) are inconclusive. The SPACE trial is a randomised non-inferiority trial comparing CEA with CAS in patients with symptomatic carotid stenosis. The primary endpoint was the risk of stroke, death, or myocardial infarction (MACE) within 30 days after randomisation. Secondary endpoints included stroke, death, or MACE within 90 days, and the need for repeat revascularisation. The trial was designed as a non-inferiority trial with a margin of 1.5%.

Methods: 1293 patients were included in the analysis. The rate of ipsilateral stroke was 1.4% in the CEA group and 1.5% in the CAS group (P=0.85). The rate of stroke, death, or MACE within 30 days was 10.1% in the CEA group and 10.3% in the CAS group (P=0.85). The rate of stroke, death, or MACE within 90 days was 11.1% in the CEA group and 11.3% in the CAS group (P=0.85). The need for repeat revascularisation was 1.4% in the CEA group and 1.5% in the CAS group (P=0.85).

Results: 1293 patients were included in the analysis. The rate of ipsilateral stroke was 1.4% in the CEA group and 1.5% in the CAS group (P=0.85). The rate of stroke, death, or MACE within 30 days was 10.1% in the CEA group and 10.3% in the CAS group (P=0.85). The rate of stroke, death, or MACE within 90 days was 11.1% in the CEA group and 11.3% in the CAS group (P=0.85). The need for repeat revascularisation was 1.4% in the CEA group and 1.5% in the CAS group (P=0.85).

Conclusion: CAS is non-inferior to CEA for the primary endpoint of stroke, death, or MACE within 30 days. The results of this trial do not support the use of CAS as an alternative to CEA.



Randomized clinical trials

CAS vs. CEA


Characteristics	SPACE (N=1196)		EVA3S (N=527)		ICSS (N=1713)		CREST (N=2502)	
	CAS	CEA	CAS	CEA	CAS	CEA	CAS	CEA
Randomized	607	589	261	259	855	858	1262	1240
Symptomatic	100%		100%		100%		53%	53%
Age (mean)	68y	68y	69y	70y	70y	70y	69y	69y
Men	72%	72%	72%	78%	70%	71%	64%	66%
History of Stroke	44%	43%	13%	20%	46%	44%	unk	unk
History of TIA	30%	31%	25%	23%	32%	35%	unk	unk
Hypertension	75%	76%	74%	73%	69%	69%	86%	86%
Diabetes mellitus	26%	28%	22%	26%	22%	22%	31%	30%
Hyperlipidemia	unk	unk	58%	56%	61%	66%	83%	86%
Stenosis <70%	37%	40%	6%	8%	11%	9%	13%	15%
Stenosis >= 70%	63%	60%	94%	92%	89%	91%	87%	85%
Contralat. Occlusion	3%	3%	5%	1%	6%	4%	3%	3%



CAS or CEA

Peri-procedural risk in randomized trials (ITT-data)

Endpoint: Any Stroke or death





Symptomatic Carotid artery stenosis

Guideline recommendations

- CEA:
 - Recommended almost in any guideline, if periprocedural risk (Stroke/death) <6% (Class I, LoE A)¹⁻⁴
- CAS
 - AHA (2011¹): indicated as an alternative to CEA ... (I,B)
 - ESC (2011²), DGN (2012⁴): may be considered as an alternative .. if death or stroke risk <6%(IIb, B)
 - RACP (2011³): may be considered as treatment option for patients who are .. unsuitable for CEA

1: Brott Th et al., Circulation (2011) 123:





2: European Heart Journal (2011) 32: 2851–2906

3: Internal Medicine Journal (2011) 41: 344-347

4: www.awmf.org: Reg-Nr. 004-028 (2012)

CEA or CAS

Long term efficacy



Eckstein HH, et al.: The Lancet. Neurology 2008; 7: 893-902 / Mas JL, et al.: Stroke 2014; 45: 2750-2756

Brott TG, et al.: The New England journal of medicine 2010; 363: 11-23/ Bonati LH, et al.: Lancet 2015; 385: 529-538



CEA or CAS

Factors for individual decision

- Patient's characteristics
 - age, type of symptoms, time since event
- Anatomical factors
 - Aortic arch configuration (esp. angulation)
 - Lesion length and -configuration
 - contra-lateral lesion (?)
- Center factors
 - Experience of center and physician
- Patient's preference



CEA or CAS for symptomatic Carotid Artery Stenosis

Summary and conclusions

- Strong evidence from randomized trials and meta-analyses that CEA is safer than CAS
- Almost twice as many strokes after CAS than after CEA
- Difference largely driven by non-disabling stroke
- Carotid endarterectomy is the treatment of choice for suitable patients with recently symptomatic carotid stenosis
- Individual factors allow to select patients also suitable for stenting

